Topics

Clinical Trials About "PCSK9 Inhibitors From Nature Lessons Clinical Utility" RSS

02:20 EDT 29th March 2020 | BioPortfolio

We list hundreds of Clinical Trials about "PCSK9 Inhibitors From Nature Lessons Clinical Utility" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "PCSK9 Inhibitors From Nature Lessons Clinical Utility" on BioPortfolio

We have published hundreds of PCSK9 Inhibitors From Nature Lessons Clinical Utility news stories on BioPortfolio along with dozens of PCSK9 Inhibitors From Nature Lessons Clinical Utility Clinical Trials and PubMed Articles about PCSK9 Inhibitors From Nature Lessons Clinical Utility for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PCSK9 Inhibitors From Nature Lessons Clinical Utility Companies in our database. You can also find out about relevant PCSK9 Inhibitors From Nature Lessons Clinical Utility Drugs and Medications on this site too.

Showing "PCSK9 Inhibitors From Nature Lessons Clinical Utility" Clinical Trials 1–25 of 13,000+

Extremely Relevant

PCSK9 Inhibitors in the Progression of Aortic Stenosis

Investigators plan evaluate whether PCSK9 inhibitors, a medication that can lower lipoprotein(a) and control dyslipidemia, can inhibit the progression of aortic stenosis, through a randomized controlled trial.


The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)

cvMOBIUS is a North American registry of patients with ASCVD aimed at understanding patterns of care in ASCVD while evaluating the real world effectiveness of PCSK9 inhibitors.

Study to Evaluate Changes in Cognitive Function in Patients Treated With PCSK9 Inhibitors

The main objective will be to evaluate the changes in the cognitive function in naive patients treated with PCSK9 inhibitors (Alirocumab and Evolocumab) by using the Montreal Cognitive Assesment questionnaire (MOCA). The secondary objectives will be: 1) To evaluate the levels of LDL-cholesterol changes from the beginning to the end of the study 2) To evaluate changes in Quality of Life among the EuroQol EQ-5D-3L questionnaire (it will also be associated to the cognitive functi...


Interest of Plasmatic Concentration Dosage of PCSK9 in Coronary Syndrome

PCSK9 (Proprotein convertase subtilisin kexin type 9) is a proconvertase playing the key-role in LDL-Cholesterol (LDLC) metabolism inhibiting the LDL receptor by a post-transcriptional way. On a functional plan, mutations "loss of function" of PCSK9 are linked to lower level of LDLC ant to a cardiovascular protection. By the way, developing pharmacologic inhibitors of PCSK9 represent an important therapeutic issue to obtain, in association with statins, the target-value...

Relevant

Treatment of Severe Infection With Antihyperlipidemia Drug

Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors increase LDL receptors by decreasing its degradation. In sepsis the pathogenic substances, endotoxin, lipoteichoic acid, phospholipomannan are the main cause of the ongoing inflammation that causes the severe damage and outcome. these substances are removed from the blood by the LDL receptors. By administering PCSK9 inhibitors to patients with sepsis/septic shock this inflammatory response can be stopped and by doing s...

Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged over the past decade as a post-transcriptional regulator of the LDL receptor (LDL-R). PCSK9 acts as an endogenous natural inhibitor of the LDL-R pathway. Monoclonal antibodies (mAb) directed against PCSK9, such as Alirocumab, are the most common method of PCSK9 inhibition. The goal of the present study is to assess, in the context of type 2 diabetes, a situation associated with an increased post-prandial hyperli...

Impact of Evolocumab in Cardiac Transplant Patients With CAV

Coronary allograft vasculopathy (CAV) is diffusely accelerated atherosclerosis of a transplanted heart. Evolocumab (repatha) is an FDA-approved drug for lowering LDL in patients who have not received a heart transplant. This drug works as a PCSK9-inhibitor. The primary objective of this study is to measure the impact of PCSK9-inhibitors on serum LDL in heart transplant patients with CAV after 12 weeks compared to baseline.

Clinical Trial Comparing Two Health Education Programs for Obese Patients (HEPO-TRIAL)

Clinical trial comparing two health education programs for obese patients in order to achieve a substantial and beneficial weight loss, using mediterranean diet. Patients will be allocated to two groups, one will receive education in diet and lifestyle, and the other one the same plus cooking lessons. The intervention period is for 6 months with monthly visits and phone and email contacts in between. An extension observation period of two years is also planned with 6 months con...

The Effects of Evolocumab in Patients With Myocardial Microvascular Dysfunction

Experimental models have linked lipid lowering therapies with systemic inflammation; however, relatively little is known about this network in clinical populations and specifically how it changes with PCSK9 inhibition. The aim of the study is to define how PCSK9 inhibition alters the circulating monocyte populations and to systematically profile the transcriptional and proteomic responses to TLRS and how these responses are modulated by PCSK9 inhibition in the peripheral blood ...

A Participatory Parental Intervention Promoting Physical Activity in Preschools

The aim of this study is to test whether a parent-focused participatory intervention in addition to gym lessons can enhance preschoolers physical activity compared to gym lessons alone.

Kinetic Study of Lp(a) and PCSK9 in Humans

The aim is to study the relationship between lipoprotein(a) [Lp(a)] and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) in humans with a kinetic study of lipoproteins in patients with dramatic increase of Lp(a) and controls.

A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

AK102 is being developed for the treatment of HoFH. The study will be conducted in 2 parts, part 1 is open label, single arm study to evaluate the safety, tolerability and efficacy of PCSK9 inhibitor AK102, and part 2 is double blind, randomized, placebo controlled study to evaluate the efficacy and safety of PCSK9 inhibitor AK102. The treatment period will last 12 week.

Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)

Atherosclerosis in the setting of HIV infection is distinct and includes increased vascular inflammation, worsened endothelial function, and a predominance of non-calcified plaque. These outcomes can be assessed using specialized noninvasive imaging which strongly predict future CV events in the general population. PCSK9 has emerged as an important pharmacologic target for cholesterol lowering in the general population and recent studies among individuals without HIV have show...

Clinical Utility of ERCP Guided Cholangiopancreatoscopy With the SpyGlass DS

This is a prospective evaluation of the clinical utility of the new cholangioscopy platform SpyGlass DS. The aims of this study are to prospectively document the clinical utility and technical aspects of ERCP with cholangioscopy and/or pancreatoscopy in the diagnosis and management of pancreata-biliary disorders.

Are Character Building Lessons Effective in Decreasing Bullying Behaviors?

Through the use of an educational intervention, the object of this study is to reduce the prevalence of bullying behaviors among fifth grade school age children. Bullying behaviors promote an environment of violence , fear, and hostility. The study will arrange to present six character education lessons in the classroom of fifth grade students in a New York City public school. Questionnaires will be administered to the students before and after all the lessons have been com...

e-Natureza Project - Affective Validation of Nature Images for Hospital Use

Randomized clinical trial about the evaluation of the use of nature photographs in the positive and negative affects of oncological patients.

Effects of Corn Oil Plus Vitamin E and B6 on LIpids, PcSk9 and Endothelial Function

This will be a randomized clinical trial carried out on subjects with suboptimal control of cholesterolemia who will consume 30 g per day of a vitaminized corn oil (plus B6 and E vitamins), in order to evaluate the effects on lipid profile, endothelial function and PCSK9

Vascular Effects of Alirocumab in Acute MI-Patients

Coronary artery disease (CAD) is the most frequent cause of mortality in the industrialized world. Hypercholesterolemia is a major risk factor for the development and progression of CAD. While statins currently represent the first-line, gold-standard therapy for primary and secondary prevention of cardiovascular morbidity and mortality, nearly 50% of patients in Europe and Canada treated with statins do not achieve their target levels of low-density lipoprotein cholesterol (LDL...

Evolocumab in Patients With STEMI

Vascular and myocardial inflammation are significantly increased in Acute Coronary Syndrome (ACS) patients, are closely correlated to LDL-C levels, and are associated with these adverse consequences in the post-ACS patient population. Serum proprotein convertase subtilisin/kerin type 9 (PCSK9) levels are also increased in ACS, may raise LDL-C, and the investigators' pre-clinical studies indicate that PCSK9 is also a potent inducer of vascular inflammation. The addition of the P...

Evolocumab in Acute Coronary Syndrome

Vascular and myocardial inflammation are significantly increased in Acute Coronary Syndrome (ACS) patients, are closely correlated to LDL-C levels, and are associated with these adverse consequences in the post-ACS patient population. Serum proprotein convertase subtilisin/kerin type 9 (PCSK9) levels are also increased in ACS, may raise LDL-C, and the investigators' pre-clinical studies indicate that PCSK9 is also a potent inducer of vascular inflammation. The addition of the P...

An Evaluation of the Safety and Clinical Utility of Handheld ECG Technology in Psychiatry

Acetylcholinesterase inhibitors and antipsychotics are drugs commonly prescribed in psychiatry, the former for dementia and the latter for acute and chronic psychotic illness. Both can cause cardiac arrhythmia therefore 12 lead ECG's are recommended before prescribing. The test is often difficult to obtain however, leading to either patients being inconvenienced or drugs prescribed without the test. There are two parts of this study, but both examine the utility of single lead ...

Nurtured in Nature

The investigators pilot test a Nature Coach Intervention in a population of postpartum women, to increase the amount of time people spend outside in local nature, with the goal of preventing postpartum depression.

PCSK9 Inhibition After Heart Transplantation

The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab when administered early after heart transplantation (HT).The main objective of this project is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when given early after HT.

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

The purpose of this study is to determine if bempedoic acid (ETC-1002) 180mg added to PCSK9 inhibitor (evolocumab) therapy is effective and safe in patients with elevated LDL cholesterol.

Feasibility of the Overground Bodyweight Supporting Walking System Andago

The overall aim of this project is to investigate the clinical utility of the Andago System, a CE certified mobile bodyweight supporting walking robot, in children with neuromotor disorders. Clinical utility encompasses practicability, acceptability, appropriateness, and accessibility. In this study, the investigators would like to investigate several aspects of clinical utility that belong to the first three components.


More From BioPortfolio on "PCSK9 Inhibitors From Nature Lessons Clinical Utility"

Quick Search